18:35 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Alzheon proposes new IPO seeking $41.2M

Alzheon Inc. (Framingham, Mass.) proposed on Aug. 27 to raise up to $41.2 million in an IPO on NASDAQ underwritten by ThinkEquity. This year, Alzheon plans to start a Phase Ib trial to evaluate the pharmacokinetics...
19:00 , May 4, 2018 |  BC Week In Review  |  Financial News

Alzheimer's company Alzheon postpones IPO

Alzheon Inc. (Framingham, Mass.) has postponed its IPO, according to a statement to BioCentury. In March, the Alzheimer's disease company had filed for a listing on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and...
20:55 , Apr 30, 2018 |  BC Extra  |  Financial News

Alzheon postpones NASDAQ IPO

Alzheon Inc. (Framingham, Mass.) has postponed its IPO, according to a statement to BioCentury. In March, the Alzheimer's disease company had filed for a listing on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and...
17:31 , Mar 23, 2018 |  BC Week In Review  |  Financial News

Alzheon proposes IPO

Alzheon Inc. (Framingham, Mass.) proposed to raise up to $80.5 million on March 16 in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and JMP Securities. Alzheon plans to start a Phase III...
19:24 , Mar 19, 2018 |  BC Extra  |  Financial News

Alzheimer's play Alzheon files for IPO

Alzheon Inc. (Framingham, Mass.) filed to raise up to $80.5 million in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and JMP Securities. Alzheon plans to start a Phase III trial this year...
21:41 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Alzheon reports Phase I bridging dose analysis data for AD candidate ALZ-801

Based on a bridging dose analysis of 3 placebo-controlled Phase I trials evaluating the safety and pharmacokinetics of various dosing regimens and formulations of Alzheimer’s disease candidate ALZ-801 in 127 healthy volunteers, Alzheon Inc. (Framingham,...
15:34 , Apr 26, 2017 |  BC Extra  |  Clinical News

Alzheon identifies MOA for AD candidate

In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for tramiprosate, the active agent in its Alzheimer's disease candidate ALZ-801. The paper showed that the compound...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
01:47 , Mar 12, 2016 |  BC Extra  |  Clinical News

Alzheon planning AD Phase III

Alzheon Inc. (Framingham, Mass.) said it plans to start Phase III testing of ALZ-801 "in the near future" to treat mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4). ALZ-801...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ALZ-801: Additional Phase III data

Pooled data from a subgroup of 252 mild to moderate AD patients homozygous for apolipoprotein E epsilon 4 ( APOE4) in a North American Phase III trial and a European Phase III trial showed...